FDA and EMA Accept Galderma’s Regulatory Filings for Nemolizumab in Patients with Prurigo Nodularis and Atopic Dermatitis

On 14 February 2024, Galderma announced that the FDA accepted its Biologics License Applications, and the EMA accepted its Marketing Authorization Applications, for use of nemolizumab in the treatment of patients with prurigo nodularis and atopic dermatitis. Galderma plans to make further regulatory submissions this year in additional countries.